Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Which factor predicts successful interval extension in eyes with nAMD switched to brolucizumab?
In patients with neovascular age-related macular degeneration (nAMD) who switched to brolucizumab treatment, those with shorter treatment interval before switching are more likely to have successful injection interval extension, as shown in a study.
Which factor predicts successful interval extension in eyes with nAMD switched to brolucizumab?
31 Jul 2023
Amblyopia protective against age-related macular degeneration
Less amblyopic individuals are more likely to have age-related macular degeneration (AMD) diagnosed on the amblyopic eye than on the nonamblyopic eye, as reported in a study. Meanwhile, individuals with lateral asymmetry tend to have the more advanced form of AMD on the nonamblyopic eye.
Amblyopia protective against age-related macular degeneration
14 Jul 2023
Patient-reported tool helps assess symptoms, vision perception after IOL implantation
Use of the 37-item Assessment of IntraOcular Lens Implant Symptoms (AIOLIS) instrument appears effective in evaluating symptoms and general perceptions of vision associated with cataract surgery and intraocular lens (IOL) implants, reports a study.
Patient-reported tool helps assess symptoms, vision perception after IOL implantation
05 Jul 2023
Newly diagnosed glaucoma ups risk of dementia
The risk of developing dementia, particularly Alzheimer’s disease (AD), is much higher among individuals with newly diagnosed glaucoma, suggests a study. Additionally, this association is much greater among older individuals.
Newly diagnosed glaucoma ups risk of dementia
03 Jul 2023
OPT-302 2.0 mg plus ranibizumab leads to superior vision gains in nAMD
Treatment with 2.0-mg OPT-302, a biologic inhibitor of vascular endothelial growth factor (VEGF)-C and D, in combination with ranibizumab, an anti‒VEGF-A inhibitor, results in greater vision gains when compared with the current standard of care for neovascular age-related macular degeneration (nAMD), reports a study. In addition, the combined therapy has an acceptable safety profile.
OPT-302 2.0 mg plus ranibizumab leads to superior vision gains in nAMD
05 Jun 2023
Dietary modification ups glaucoma risk in women
Dietary modification (DM) among individuals in the lowest quartile for percentage calories from total fat at baseline is associated with a higher risk of incident primary open-angle glaucoma (POAG) among women, irrespective of age or race, suggests a recent study.